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ABSTRACT 
Fibrinogen, a protein involved in blood coagulation, is very susceptible to oxidation. Oxidation 
alters its function and usually makes it more thrombogenic. Bilirubin, an end-product of the 
haem degradation in vertebrates, is known for its antioxidant properties. The present paper 
describes interaction between fibrinogen and bilirubin, and the influence of bilirubin on the 
formation of fibrin and protection against oxidation. The binding constant of 4.5 x 104 M-1 was 
determined for the fibrinogen/bilirubin complex at 37 °C. There is no change in secondary and 
tertiary structure of fibrinogen or its thermal stability upon bilirubin binding. The binding site of 
fibrinogen is not stereospecific for bilirubin and is able to accommodate both bilirubin 
conformers. A change in absorption maximum of bilirubin occurs upon its interaction with 
fibrinogen, suggesting an alteration in the conformation of bilirubin to the more cyclic one. 
Bilirubin exerts antioxidant effect on fibrinogen, preventing its carbonylation and aggregation. 
The presence of bilirubin induces the formation of fibrin with thicker fibres, as assessed by the 
coagulation assay. Fibrinogen and bilirubin interact at physiological concentrations, bilirubin 
may act as an antioxidant for fibrinogen and may modulate an important event in haemostasis, 
which altogether suggests possible physiological relevance of this interaction. 
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1. INTRODUCTION 
Fibrinogen or factor I is a fibrillar protein with molecular mass of 340 kDa, composed of three 
pairs of chains forming (AαBβγ)2 structure [1]. Its main physiological role is in coagulation and 
it participates in both primary and secondary haemostasis. In primary haemostasis, fibrinogen 
enables platelet aggregation by the formation of bridges due to its interaction with IIIa/IIb 
glycoprotein [2]. In secondary haemostasis, fibrinogen is a precursor of the insoluble fibrin 
network which stabilises platelet clot [3]. In order to fulfil their roles, fibrinogen and fibrin 
interact with other proteins, ions and small molecules, which regulate the formation of fibrin and 
its degradation [4]. Fibrinogen interacts with tissue factors and cytokines, such as fibroblast 
growth factor-2, vascular endothelial growth factor and interleukin-1β [3]. Hyaluronic acid and 
S-nitrosoglutathione are able to bind to fibrinogen and fibrin causing modulation of their 
functions [5,6]. 
Fibrinogen is very susceptible to oxidation [7], which significantly affects its function. 
Oxidatively modified fibrinogen, both in vivo and in vitro, becomes thrombogenic and more 
resistant to fibrinolysis compared to the unmodified molecule [8-11]. Fibrinogen undergoes 
glyco-oxidation in diabetes and related diseases causing formation of fibrin which is less 
efficient in the activation of plasmin and more resistant to hydrolysis [12]. There are, however, 
reports on the increased fibrinolysis and reduced clot strength caused by the oxidation of 
fibrinogen [13]. Therefore, fibrinogen oxidation, its consequences, mechanisms involved in the 
regulation and possible prevention of oxidation deserve further attention of the researchers and 
clinicians.   
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Bilirubin, a tetrapyrrole pigment and a degradation product of the haem metabolism [14], has an 
antioxidant potential. Even very low, nanomolar concentrations of bilirubin in tissues may exert 
protective effect against oxidation in cooperation with biliverdin reductase in the biliverdin-
bilirubin cycle [15]. Taking into consideration the susceptibility of fibrinogen to oxidation and 
antioxidant properties of bilirubin, the interaction between these two molecules under 
physiological condition was investigated in this study, together with the consequences of 
bilirubin binding on the structure and stability of fibrinogen, fibrin formation and protection 
against oxidation.  
 
2. MATERIALS AND METHODS 
2.1 Materials 
All substances used were purchased from Sigma-Aldrich (Germany). Fibrinogen was 
additionally purified: the commercial preparation was dissolved in 50 mM phosphate buffer (PB) 
pH 7.3, precipitated by the saturated ammonium sulphate solution (at the final concentration of 
25 %), dissolved again in PB and dialysed against the same buffer at 4 °C overnight. The purity 
of fibrinogen was confirmed by the reducing SDS-PAGE (Supplementary Fig 1). 
The concentration of fibrinogen (determined at 280 nm using the extinction coefficient of 15.1) 
in different experiments was different, and it was adjusted according to the analytical 
requirements of a specific method and the instrument. Bilirubin was dissolved in either DMSO 
or 10 mM NaOH, but the final concentration of DMSO in reaction mixtures was below 1 %. All 
measurements, unless otherwise stated, were performed in duplicate immediately after mixing of 
the reactants.  
2.2 Spectrofluorometric analysis of the fibrinogen/bilirubin interaction 
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The fluorescence data were obtained using FluoroMax®-4 spectrofluorometer (Horiba Scientific, 
Japan) at 37 °C. Fibrinogen (20 nM) was enabled to interact with different amounts of bilirubin 
dissolved in DMSO (0 – 20 μM). The excitation wavelength was chosen to be 280 nm 
(excitation of 41 tryptophan (Trp) and 67 tyrosine (Tyr) residues contributing to the intrinsic 
fluorescence of the protein) and the emission spectra were obtained in the range from 290 to 450 
nm, with the slits width of 5 nm. Specific fluorescence obtained for each reaction pair was 
corrected for the background signal originating from the bilirubin itself. The differences in 
fluorescence intensities due to the inner-filter effect were corrected using the following equation 
[16]: 
Fc = Fo x 10(Aem+Aex)/2 (1) 
where Fc is the corrected fluorescence, Fo is the measured fluorescence, Aem and Aex 
correspond to the absorbance at the emission (340 nm) and the excitation (280 nm) peaks.  
The binding constant, Ka, for the fibrinogen/bilirubin complex was calculated using the 
following equation: 
log
F0-F
F
 = - nlog
1
[L] -[P] 
F0-F
F0
 
+nlogKa (2) 
where F0 and F are the emission signals of the protein (fibrinogen) in the absence and in the 
presence of the ligand (bilirubin), while [L] and [P] correspond to the total concentrations of the 
ligand (bilirubin) and the protein (fibrinogen). 
2.3 UV-VIS spectrometric analysis of the fibrinogen/bilirubin interaction 
UV-VIS spectrometric characterisation of the fibrinogen/bilirubin complex was performed using 
ND-2000c microvolume spectrophotometer (Thermo Fisher Scientific, USA), in the range of 
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330-600 nm at room temperature. Spectra were recorded for fibrinogen (4 μM), bilirubin (36 
μM) and their mixtures containing 2 or 4 μM fibrinogen and 36 μM bilirubin.  
2.4 Analysis of the thermal stability of the fibrinogen/bilirubin complex 
The influence of bilirubin on the thermal stability of fibrinogen was analysed using the same 
instrument as in section 2.2. Fibrinogen denaturation is characterised by a red shift of its 
emission peak at 340 nm. The ratio between fluorescence intensities at 348 and 333 nm increases 
with temperature, enabling investigation of the thermal stability of fibrinogen. The temperature 
dependence of the fluorescence of fibrinogen, alone (50 nM) or in the presence of bilirubin (20 
μM), was studied in the temperature range of 37 to 87 °C, with the rate of the temperature 
increase of 2 °C/min (the equilibration period was set to 1 min). The results were expressed as 
the change of the ratio F348/F333 with the temperature and presented as a sigmoidal function. The 
inflection point in the plot was considered as the melting temperature (Tm) of fibrinogen. 
2.5 CD spectrometric analysis of the fibrinogen/bilirubin interaction 
CD spectrometric characterisation of the fibrinogen/bilirubin complex was performed using J-
815 spectropolarimeter (Jasco, Japan), at 37 °C and a scan speed of 50 nm/min. The near-UV 
measurements were performed in the range of 250-350 nm with the cell path of 1 cm. The 
concentration of fibrinogen was kept constant (4 μM) while the concentration of bilirubin was 
varied (18, 36 and 54 μM). For the far-UV measurements (185-260 nm, 0.1 cm cell path), the 
same concentrations of fibrinogen and bilirubin were tested, however this time bilirubin was 
dissolved in 10 mM NaOH, as DMSO interferes at these wavelengths.   
2.6 Investigation of the protective effect of bilirubin against oxidation of fibrinogen 
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In this experiment, 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) was used as an 
oxidising reagent. The oxidation of fibrinogen (3 μM, 1 mL) was performed using AAPH (at the 
final concentration of 5 mM) in the absence and in the presence of bilirubin (6 µM dissolved in 
10 mM NaOH). The reaction mixture was incubated at 37 °C and 200 μL aliquots were taken at 
defined time intervals (Fig 4). An ice-cold 20 % TCA (200 µL) was added to each aliquot and 
the proteins precipitated by centrifugation at 12000 x g for 20 min. The obtained pellet was 
washed with an ice-cold acetone (400 μL), centrifuged again and dissolved in the sample buffer 
for the non-reducing PAGE. The proteins were resolved by the native PAGE using 8 % gel and 
transferred on the poly(vinylidene fluoride) membrane (PVDF). Protein carbonyls were 
derivatised in situ using dinitrophenylhydrazine (DNP) and immunoblotted using anti-DNP 
antibody [17,18].       
2.7 Investigation of the effect of bilirubin binding to fibrinogen on its coagulation 
A coagulation assay, i.e. the formation of fibrin from fibrinogen, was conducted in a microtiter 
plate using Victor3V multilabel reader (PerkinElmer, USA) at the room temperature. The 
coagulation of fibrinogen (3 μM) was performed using CaCl2 (at the final concentration of 2.2 
mM) and thrombin (1 IU/mL) in the absence and in the presence of bilirubin (6 µM dissolved in 
10 mM NaOH). The absorbance of the mixture containing all reactants except fibrinogen was 
also recorded and used to correct the corresponding result obtained in the presence of fibrinogen. 
The preliminary testing confirmed that 10 mM NaOH had very little effect on the formation of 
fibrin. The coagulation process was monitored at 350 nm, at 10 sec intervals for 8 min. All 
measurements were performed in triplicate.      
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3. RESULTS 
3.1 Spectrometric analysis of the fibrinogen/bilirubin interaction 
The interaction between bilirubin and fibrinogen caused the concentration-dependent reduction 
of the intrinsic fluorescence of fibrinogen (Fig 1A). Using the quenching data, a binding constant 
for the fibrinogen/bilirubin complex was determined to be 4.5 x 104 M-1 at 37 ºC (Fig 1B). No 
shift in the emission spectra maximum was observed as a consequence of the bilirubin binding, 
suggesting that amino acids Tyr and Trp in fibrinogen remain in the same or very similar 
environment in the native and bilirubin-bound protein. UV-VIS spectrometry confirmed the 
existence of the fibrinogen/bilirubin interaction. The absorption maximum of bilirubin became 
wider and a red shift was observed in the presence of either 2 or 4 μM fibrinogen, although it 
was more pronounced in the presence of the higher concentration of the protein (Fig 1C).  
3.2 Analysis of the thermal stability of the fibrinogen/bilirubin complex 
As explained in the section 2.4, thermal denaturation of fibrinogen induces a red shift of its 
emission peak. Experiments with fibrinogen and fibrinogen/bilirubin complex have shown no 
difference in their thermal stability, i.e. the melting points were calculated to be 54 ºC in both 
cases (Fig 2). This result indicated that bilirubin binding does not affect fibrinogen stability.  
3.3 CD spectrometric analysis of the fibrinogen/bilirubin interaction 
Results obtained using CD-spectrometry confirmed the previously obtained data. Near-UV CD 
spectra (Fig 3A) and far-UV CD spectra (Fig 3B) confirmed that bilirubin binding to fibrinogen 
does not affect its tertiary or secondary structure. The far-UV CD spectrum, which results from 
the absorption originating from the α-helix secondary structure of fibrinogen remained almost 
unchanged upon its interaction with bilirubin.  
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3.4 Investigation of the protective effect of bilirubin on the oxidation of fibrinogen 
Incubation of fibrinogen with AAPH induced oxidation which resulted in a partial protein 
aggregation (Fig 4A). The addition of bilirubin reduced a degree of fibrinogen modification 
during the first hour of the oxidative attack, but after two hours bilirubin was much less efficient 
in preventing protein aggregation (Fig 4A). Derivatization of the protein carbonyls (i.e. oxidative 
modifications) with DNP and their subsequent detection with anti-DNP antibody confirmed the 
existence of the lower amount of fibrinogen carbonyl groups in the presence of bilirubin (Fig 4B 
and 4C). Another indicator of the bilirubin interaction was the colour of the solution - after two 
hours of incubation bilirubin lost its yellow colour. 
3.5 Investigation of the effect of bilirubin binding to fibrinogen on its coagulation 
A coagulation assay demonstrated that bilirubin binding to fibrinogen affected the formation of 
fibrin (Fig 5). The initial speed of fibrin formation and the coagulation times for fibrinogen and 
fibrinogen/bilirubin complex were very similar, whereas the maximal absorbance of the fibrin 
formed in the presence of bilirubin was much higher than the absorbance of the fibrin formed 
from fibrinogen alone. This finding implicated that thicker fibrin fibres form in the presence of 
bilirubin. 
 
4. DISCUSSION 
A newly discovered interaction between fibrinogen and bilirubin is described in this paper. 
Bilirubin in blood, at the concentration up to 30 μM in healthy persons [19], is predominantly 
bound to albumin with a high affinity constant that ranges from 6.7 x 106 to >108 M-1. The 
binding constant is concentration- and temperature-dependent [20]. The affinity of bilirubin for 
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fibrinogen is much lower and is calculated to be 4.5 x 104 M-1. According to our results, bilirubin 
binding to fibrinogen does not influence the structure or the melting point of fibrinogen [21]. 
Phycocyanobilin, a molecule with the structure similar to bilirubin, binds to and stabilises human 
serum albumin (HSA) by increasing its α-helical content and the melting point [22]. 
In aqueous solution, bilirubin exists in an equimolar ratio of M and P ridge tile conformers. It is 
known that stereoselective binding of the P conformer to HSA induces optical activity, i.e. a 
positive Cotton effect in the CD spectra of the HSA/bilirubin complex [23]. According to our 
results (data not shown), the formation of fibrinogen/bilirubin complex is not accompanied by a 
stereoselective binding of this pigment. Therefore, the binding site of fibrinogen is not 
stereospecific for bilirubin and is able to accommodate both conformers. 
When added to a solution of fibrinogen, a red shift of the absorption maximum of bilirubin was 
observed together with the change in the shape of the peak, suggesting an alteration in the 
conformation of bilirubin upon its binding to fibrinogen. Spectrometric calculations predict that a 
transition of bilirubin from a ridge tile to a more cyclic conformation is accompanied by a red 
shift of its absorption maximum [23]. Therefore, the results presented in this work suggest that 
bilirubin bound to fibrinogen probably exists in a more cyclic conformation. A similar shift was 
observed upon bilirubin binding to HSA [24-26]. In contrast to the HSA/bilirubin complex, 
which was characterised by a large increase in the fluorescence of bilirubin [27], this 
phenomenon was not observed in the case of the fibrinogen/bilirubin complex (data not shown). 
Since the fluorescence correlates with a degree of structural rigidness and the binding of bilirubin 
to fibrinogen is much weaker than to HSA, it can be postulated that the binding to fibrinogen 
does not affect a conformational freedom of bilirubin significantly and, hence, its fluorescence.  
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Certain pathophysiological conditions are characterised by an increased oxidative stress. 
Oxidation alters the structure and function of proteins [28]. Fibrinogen is very susceptible to 
oxidation which usually makes it more thrombogenic. An increased oxidation of fibrinogen was 
detected in patients with myocardial infarction, cirrhosis or diabetes mellitus [10,12,29]. An 
oxidative stress affects the entire coagulation system causing an increase in the reactivity of 
platelets and a dysfunction of the endothelium [30]. In order to investigate a possible protective 
role of bilirubin binding against the oxidation of fibrinogen, reactants were mixed at their 
physiological concentrations and ratios. An antioxidant effect of bilirubin was clearly 
demonstrated, as the presence of bilirubin prevented carbonylation and aggregation of 
fibrinogen.    
Beneficial effects of bilirubin on the human health were reported in several studies. A negative 
correlation was found between its concentration and an incidence of the colorectal cancer [31] or 
prediabetes [32]. In the patients with diabetes and Gilbert syndrome, whose bilirubin 
concentrations may reach up to 90 μM [33], a decrease in the oxidation of proteins was recorded 
[34]. Bilirubin was recognised as an endogenous antioxidant in human endothelial cells [35] and 
its concentration is negatively correlated with the concentration of fibrinogen and plasminogen 
activator inhibitor-1 [36]. 
In order to investigate a potential effect of bilirubin bound to fibrinogen, a coagulation assay was 
performed (again, using physiological concentrations and ratios of fibrinogen and bilirubin). The 
presence of bilirubin induced formation of thicker fibrin fibres, affecting its branching and 
permeability, since it is known that thinner fibres result in higher branching and reduced 
permeability [10,37]. When permeability is reduced, plasmin cannot efficiently penetrate in the 
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clot, leading to a prolonged degradation time of fibrin and an increased risk of the formation of 
thrombus [28]. The effect of bilirubin on the formation of fibrin was the same as the effect of the 
aspirin treatment [38]. The data obtained in our study point to bilirubin as a beneficial modulator 
of haemostasis and a protector of fibrinogen against oxidation. Although fibrin with thicker 
fibres usually has higher permeability, other factors may influence the final outcome [11,39]. 
One should keep in mind that the coagulation assay employed in this work was based on the 
purified fibrinogen and a commercially available thrombin. Many other factors present in blood 
influence the formation of fibrin [4]. Nevertheless, fibrinogen and bilirubin interact at 
physiological concentrations, bilirubin may protect fibrinogen against oxidation and may 
modulate fibrin formation, which altogether suggests a possible physiological relevance of this 
interaction.   
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Figure legends 
Fig 1. The emission spectra of fibrinogen in the absence and in the presence of different 
concentrations of bilirubin (A). Determination of the binding constant of the fibrinogen/bilirubin 
complex (B). UV-VIS spectra of bilirubin, fibrinogen and bilirubin/fibrinogen complex (C). 
Fig 2. Determination of the melting point of fibrinogen and the fibrinogen/bilirubin complex; the 
ratio of fluorescence intensities at 348 and 333 nm (F348/F333) was calculated. The inflection 
point on the curve corresponds to the melting point. 
Fig 3. Near-UV (A) and far-UV (B) CD spectra of fibrinogen in the absence and in the presence 
of bilirubin. 
Fig 4. Determination of the susceptibility of fibrinogen to oxidation with AAPH in the absence (-
) and in the presence (+) of bilirubin during 4 h. A native PAGE and a transfer to the PVDF 
membrane was performed, followed by the protein staining with Ponceau S (A), and 
derivatization of the protein carbonyls with DNP and immunoblotting with anti-DNP antibody 
(B). The ratio of densitometric signals obtained by immunoblotting and Ponceau S staining (C) 
(there was no protein detected by Ponceau S staining after 240 min, although an immunoreactive 
signal with anti-DNP antibody was recorded).     
Fig 5. Determination of the effect of bilirubin on the formation of fibrin in the coagulation assay.
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Supplementary figure 
 
Supplementary Fig.1. Ponceau S staining of the purified fibrinogen purchased from Sigma-
Aldrich after reducing SDS-PAGE and transfer to PVDF membrane.    
